JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

JNJ

225.55

+0.06%↑

UNH

364.08

-1.27%↓

TMO

465.22

+0.09%↑

ISRG

452.75

+0.48%↑

ABT

87.25

-1.3%↓

Home・Elenco Azioni・Eli Lilly and Co.

Eli Lilly and Co.

Aperta

SettoreSettore sanitario

978.62 2.31

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

953.98

Massimo

977.98

Metriche Chiave
By Trading Economics
Entrata	1.1B 6.6B
Vendite	1.7B 19B
P/E Media del settore	37.883 67.147
EPS	7.54
Rendimento da dividendi	0.68
Margine di Profitto	34.406
Dipendenti	50,000
EBITDA	506M 8.4B

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+30.61% upside

Dividendi
By Dow Jones
Rendimento da dividendi Media del settore	0.68% 2.36%
Prossima data del Dividendo	9 giu 2026
Prossima data del' Ex Dividendo	15 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-160B 776B
Apertura precedente	976.31
Chiusura precedente	978.62

Notizie sul Sentiment di mercato

By Acuity

61%

39%

306 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

N/A / 884.54 Supporto e resistenza

Eli Lilly and Co. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 apr 2026, 12:01 UTC

Utili

I principali Market Mover

Eli Lilly Shares Jump On Guidance Boost, Earnings Above Expectations

30 apr 2026, 20:59 UTC

Azioni calde

Stocks to Watch Recap: Blue Owl, Alphabet, Qualcomm, Meta Platforms -- WSJ

30 apr 2026, 20:12 UTC

Utili

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 16:43 UTC

Utili

Eli Lilly Shares Jump 10% as Mounjaro, Zepbound Fuel Massive Growth -- WSJ

30 apr 2026, 16:10 UTC

Discorsi di Mercato

Eli Lilly Expecting A Push to Extend Medicare GLP-1 Coverage -- Market Talk

30 apr 2026, 15:13 UTC

Utili

Update: Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 14:58 UTC

Utili

Lilly CEO: Direct-to-Consumer Channel Popularity Will Continue, Become Useful in Other Kinds of Drugs

30 apr 2026, 14:53 UTC

Utili

Lilly Expects Government to Push to Get GLP-1 Medicare Coverage for 2028, CEO Says

30 apr 2026, 14:50 UTC

Utili

Lilly Expects Strong Persistence in Medicare Population for GLP-1s, President of Lilly USA Says

30 apr 2026, 14:42 UTC

Utili

Gaining Incremental Market Share in GLP-1s Getting Harder, President of Lilly International Says

30 apr 2026, 14:39 UTC

Utili

Lilly CEO: GLP-1 Unit Economics Dependent on Fixed Costs Unmoved by Volume

30 apr 2026, 14:35 UTC

Utili

Lilly CEO: GLP-1 Price Cuts Result in Large Volume Expansions

30 apr 2026, 14:24 UTC

Utili

Lilly to Begin Full-Scale Consumer Promotion, Including TV Ads, of Foundayo in 3Q, CFO Says

30 apr 2026, 14:17 UTC

Utili

Lilly CFO: Loss of Medicaid Access in Some States Hurt 1Q Prescription Growth By High Single Digits

30 apr 2026, 13:56 UTC

Utili

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 13:37 UTC

Azioni calde

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 apr 2026, 12:32 UTC

Discorsi di Mercato

Utili

Eli Lilly CEO Says Early Foundayo Results Are Strong -- Market Talk

30 apr 2026, 12:29 UTC

Discorsi di Mercato

Utili

Eli Lilly CEO Says Foundayo Adoption Could Take Time -- Market Talk

30 apr 2026, 12:23 UTC

Discorsi di Mercato

Utili

Eli Lilly CEO Says International Demand for GLP-1s Is Ramping Up -- Market Talk

30 apr 2026, 12:10 UTC

Utili

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 12:08 UTC

Utili

Eli Lilly Sales, Profits Surge on Weight-Loss Drugs -- WSJ

30 apr 2026, 12:04 UTC

Discorsi di Mercato

Utili

Eli Lilly's GLP-1 Party Has No End in Sight -- Market Talk

30 apr 2026, 11:39 UTC

Azioni calde

Stocks to Watch: Alphabet, Qualcomm, Meta Platforms, Eli Lilly -- WSJ

30 apr 2026, 11:08 UTC

Utili

Eli Lilly Stock Jumps on Earnings Beat as Zepbound and Mounjaro Sales Skyrocket -- Barrons.com

30 apr 2026, 10:50 UTC

Utili

Eli Lilly Raises 2026 Performance Margin View to 47%-48.5% From 46%-47.5% >LLY

30 apr 2026, 10:49 UTC

Utili

Eli Lilly Had Seen 2026 Revenue $80B-$83B, Adjusted EPS $33.50-$35.00 >LLY

30 apr 2026, 10:48 UTC

Utili

Eli Lilly 1Q Gross Margin 81.9% >LLY

30 apr 2026, 10:48 UTC

Utili

Eli Lilly 1Q Volume Rose 65% >LLY

30 apr 2026, 10:47 UTC

Utili

Eli Lilly Raises 2026 View To Adj EPS $35.50-Adj EPS $37.00 >LLY

30 apr 2026, 10:46 UTC

Utili

Eli Lilly Raises Full-Year Guidance >LLY

Confronto tra pari

Modifica del prezzo

Eli Lilly and Co. Previsione

Obiettivo di Prezzo

By TipRanks

30.61% in crescita

Previsioni per 12 mesi

Media 1,258.2 USD 30.61%

Alto 1,500 USD

Basso 850 USD

Basato su 22 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Eli Lilly and Co. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

22 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 22 che hanno fornito valutazioni azionarie a Eli Lilly and Co. - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 884.54Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

306 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.